Compare BMEA & NRDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | NRDY |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | 41 | 500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 99.7M |
| IPO Year | 2021 | 2020 |
| Metric | BMEA | NRDY |
|---|---|---|
| Price | $1.52 | $0.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $8.86 | $1.00 |
| AVG Volume (30 Days) | ★ 1.3M | 641.8K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | 13.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | N/A | $8.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.77 |
| 52 Week High | $3.07 | $1.90 |
| Indicator | BMEA | NRDY |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 39.65 |
| Support Level | $1.22 | $0.78 |
| Resistance Level | $1.66 | $0.99 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 86.54 | 30.86 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Nerdy Inc operate a next-generation live tutoring and intervention platform that leverages the power of human expertise with Developed artificial intelligence (AI) to personalize learning, accelerate student achievement, and empower educators. The company's proprietary platform leverages technology, including AI, to connect learners with instructors across a wide range of subjects and formats, including subscription-based learning, one-on-one instruction, small group tutoring, large-format classes, and assessments. Its flagship business operates under the Varsity Tutors brand. The company's offerings are available directly to students and consumers, as well as through schools and other institutions.